Dechra Pharmaceuticals PLC/Osurnia business of Elanco Animal Health Incorporated Merger Inquiry

The CMA investigated and cleared the anticipated acquisition by Dechra Pharmaceuticals PLC of the Osurnia business of Elanco Animal Health Incorporated.

From:
Competition and Markets Authority
Published
26 March 2020
Last updated
15 July 2020 — See all updates
Case type:
Mergers
Case state:
Closed
Market sector:
Pharmaceuticals
Outcome:
Mergers - phase 1 clearance
Opened:
26 March 2020
Closed:
15 July 2020

Statutory timetable

Phase 1 date Action
9 June 2020 Decision announced
20 April 2020 Launch of merger inquiry
26 March 2020 to 17 April 2020 Invitation to comment

Phase 1

CMA clearance decision

9 June 2020: The CMA has cleared the anticipated acquisition by Dechra Pharmaceuticals PLC of the Osurnia business of Elanco Animal Health Incorporated.

Launch of merger inquiry

20 April 2020: The CMA announced the launch of its merger inquiry by notice to the parties.

Invitation to comment: Now closed

26 March 2020: The CMA is considering whether it is or may be the case that this transaction, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.

Contact

Please send written representations about any competition or public interest to general.enquiries@cma.gov.uk.

Published 26 March 2020
Last updated 15 July 2020 + show all updates

  1. Full text decision published following the 9 June announcement that the CMA has cleared the anticipated acquisition.

  2. Clearance decision announced.

  3. Launch of merger inquiry announced.

  4. First published.